Context Therapeutics (CNTX) News Today $1.00 +0.06 (+5.97%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period William Blair starts Context Therapeutics stock with OutperformApril 23 at 7:26 PM | uk.investing.comContext Therapeutics (NASDAQ:CNTX) Now Covered by William BlairWilliam Blair started coverage on Context Therapeutics in a report on Monday. They set an "outperform" rating on the stock.April 23 at 9:20 AM | marketbeat.comWilliam Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform RecommendationApril 22 at 2:26 AM | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of "Buy" by AnalystsContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy ratinApril 20, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of "Buy" from BrokeragesApril 18, 2025 | americanbankingnews.comContext Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Trimmed by Affinity Asset Advisors LLCAffinity Asset Advisors LLC lessened its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 23.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,015,340 shares of the compaApril 17, 2025 | marketbeat.comFranklin Resources Inc. Purchases 2,149,392 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)Franklin Resources Inc. lifted its position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 115.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,003,380 shares of the compaApril 14, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.comContext Therapeutics doses first patient in Phase 1 trial of CT-95April 10, 2025 | markets.businessinsider.comContext Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing CancersApril 10, 2025 | msn.comContext Swoons on CT-95 First DoseApril 9, 2025 | baystreet.caContext Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95April 9, 2025 | globenewswire.comContext Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95April 9, 2025 | globenewswire.comZacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and LeidosApril 4, 2025 | finance.yahoo.comContext Therapeutics to Participate in Upcoming Investor ConferencesApril 1, 2025 | globenewswire.comContext Therapeutics to Showcase CT-95 Data at AACR 2025March 28, 2025 | msn.comContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025March 26, 2025 | globenewswire.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Buy" from AnalystsContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recMarch 24, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CNTX Q3 Earnings?Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Context Therapeutics in a research report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar anticipates that the company will postMarch 24, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX)March 23, 2025 | markets.businessinsider.comContext Therapeutics Reports 2024 Results and Outlines Clinical AdvancementsMarch 22, 2025 | msn.comCompanies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In GrowthMarch 22, 2025 | finance.yahoo.comContext Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings ResultsContext Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01.March 22, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Friday.March 22, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday.March 22, 2025 | marketbeat.comContext Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025March 20, 2025 | quiverquant.comContext Therapeutics Reports Full Year 2024 Operating and Financial ResultsMarch 20, 2025 | globenewswire.comContext Therapeutics (CNTX) to Release Earnings on ThursdayContext Therapeutics (NASDAQ:CNTX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from BrokeragesShares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given aFebruary 27, 2025 | marketbeat.comContext Therapeutics Inc.: Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2025 | finanznachrichten.deContext Therapeutics (NASDAQ:CNTX) Shares Up 2.1% - Time to Buy?Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% - Should You Buy?February 25, 2025 | marketbeat.comContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 24, 2025 | globenewswire.comContext Therapeutics to Showcase at Top 2025 Investor ConferencesFebruary 22, 2025 | msn.comContext Therapeutics to Participate in Upcoming Investor ConferencesFebruary 19, 2025 | globenewswire.comCentrexion stock hits 52-week low at $0.79 amid market challengesFebruary 11, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by BrokeragesShares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a stFebruary 2, 2025 | marketbeat.comFranklin Resources Inc. Acquires Additional Shares in Context Therapeutics Inc.January 27, 2025 | gurufocus.comBreakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted TherapyJanuary 18, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest UpdateContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,530,000 shares, an increase of 55.1% from the December 15th total of 986,300 shares. Based on an average daily volume of 501,500 shares, the short-interest ratio is presently 3.1 days. Currently, 2.6% of the shares of the stock are sold short.January 17, 2025 | marketbeat.comContext Therapeutics Welcomes Andy Pasternak as New Chairman of the BoardJanuary 17, 2025 | msn.comContext Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76January 15, 2025 | finanznachrichten.deD. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)D. Boral Capital restated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Wednesday.January 15, 2025 | marketbeat.comContext doses first patient in Phase 1 clinical trial evaluating CTIM-76January 14, 2025 | markets.businessinsider.comContext Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76January 14, 2025 | globenewswire.comContext Therapeutics Appoints Andy Pasternak As Board ChairmanJanuary 13, 2025 | markets.businessinsider.comContext Therapeutics Inc. Appoints Andy Pasternak as Chairman of the Board to Drive Company's Growth in T Cell Engager DevelopmentJanuary 13, 2025 | quiverquant.comContext Therapeutics Appoints Andy Pasternak as Chairman of the Board of DirectorsJanuary 13, 2025 | globenewswire.comJMP Securities Initiates Coverage of Context Therapeutics (CNTX) with Market Outperform RecommendationJanuary 9, 2025 | msn.comContext Therapeutics (NASDAQ:CNTX) Upgraded to Strong-Buy at Citizens JmpCitizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday.January 9, 2025 | marketbeat.comInnovative Growth Potential: Silvan Tuerkcan’s Buy Rating on Context TherapeuticsJanuary 8, 2025 | markets.businessinsider.com Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.810.72▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼82▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TRDA News ARCT News TSHA News HRTX News ATYR News ATAI News PVLA News AURA News CYRX News GLUE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.